Omeprazole Sodium for Injection (40mg)

Prod Model:	40mg

Founded in 1996, Sichuan Kelun Pharmaceutical Co., Ltd. has grown into a modern pharmaceutical group, owning 16 subsidiaries (branches) within and outside Sichuan Province, after rapid 13 years' development. Due to the special characteristics of logistics of IV solution industry, the production bases of Kelun Pharmaceutical are located in 9 provinces and regions of China, such as Sichuan, Hunan, Heilongjiang and Yunnan, all of which have become local major tax payers and key enterprises and totally offer employment opportunities for more than 10 thousand employees. The sales revenue of Kelun Pharmaceutical in 2008 exceeded RMB 2.6 billion, and profit tax was RMB 600 million.

Kelun Pharmaceutical manufactures and sells drugs in 368 varieties of 16 types, including IV solutions, small volume injection, sterile powder for injection, lyophilized powder for injection, tablets, capsules, granules and oral solutions, among which 220 products in 95 varieties belong to IV solutions, and we have the largest number of product varieties and packaging forms in the IV solution industry of China. In 2007, classified by clinical applications of IV solution products, the market share of the 12 leading products of Kelun Pharmaceutical ranked at the first place in China; Classified by packaging forms, IV solution products in glass bottle and PP bottle both ranked at the first place in China and IV solutions in soft bag ranked at top three in China.

Kelun is one of the largest professional manufacturers of IV solutions around the world, enjoying market share higher than 20% with our products in China and lots of faithful clients. The praise from hundreds of millions of users has well established the solid "Kelun" brand. "Kelun" brand was identified as "famous trademark" by China Trademark Office (CTMO) in April, 2009. Our products are exported to 6 overseas markets, such as Southeast Asia and Kazakhstan, where the products are extremely popular. Kelun Pharmaceutical cooperates with Sagent Pharmaceuticals of the USA to explore the USA IV solution market together, which will set up a new milestone for recognition on quality reputation and in the medical course of Kelun Pharmaceutical.

Sticking to the Corporate Tenet of 'seeking scientific truth and pursuing ethical virtue', Kelun Pharmaceutical has primarily established harmonious development consciousness, in which the primary distribution gives priority to efficiency, second distribution gives priority to tax to government, and third distribution gives priority to charity. Kelun has donated tens of millions of Yuan (in which nearly 30 million Yuan was donated to the affected people in the '5.12' Wenchuan Earthquake) for social welfare undertakings, China Guangcai Program and disadvantaged groups over the past years, demonstrating our wealth views and sense of social justice as well as a virtuous and healthy track of development of an excellent private enterprise in the market economy.

Kelun Pharmaceutical will make full use of the market network covering the whole China, bring the existing advantages in technologies, product system, quality, raw material supply and R&D ability into play, and continuously adjust and optimize product structure, to further increase market share in domestic IV solution industry. In the meantime, we actively promote development of other products (non-IV solution products), seek new growth points in scale and profits, continuously strengthen competitiveness of our company, and strive for developing ourselves into a pharmaceutical manufacturer with the largest scale, the most complete varieties and types, the highest profitability and the most powerful competitiveness.